Glutamate Reducing Interventions in Schizophrenia

• Status: Suspended
• Trial end date: 2022-09-30
• Target enrollment: 0
• Participant gender: All

Summary

Participants will be administered several doses of POMA (low and high doses) over 14 days to individuals at clinical high risk for developing psychosis and use MRI brain imaging to determine whether these doses of POMA are affecting glutamate levels.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York State Psychiatric Institute
• Collaborator: National Institute of Mental Health (NIMH)

Criteria

Inclusion Criteria:

• Capacity to provide informed consent

• Currently using a reliable form of birth control

Exclusion Criteria:

• Metal implants in body or a history of metal working

• Lifetime diagnosis of asthmatic symptoms within the past 3 years or known sensitivity to contrast agents

• Lifetime diagnosis of renal failure/disease

• Acute neurological, neuroendocrine, or medical disorder including renal insufficiency (CrCl<40 mL/min/1.73m2)

• Lifetime diagnosis of hypertension or diabetes or seizure disorder

• IQ<70

• Acute risk for suicide and/or violence

• Pregnant lactating

• Current abuse of substances (alcohol, cocaine, stimulants, cannabis, opiates, sedative hypnotics)

• Current use or anticipated need for antipsychotics or mood stabilizers (all antipsychotics, also depakote, lithium, lamotrogine, pregabalin or any med with a mechanism of action like gabapentin), probenecid, selective serotonin reuptake inhibitors, tricyclic antidepressants, and monoamine oxidase inhibitors

• More than one previous gadolinium scan